Amneal Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(unaudited; in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net revenue | $862,684 | $784,513 | $2,381,400 | $2,204,441 |
| Cost of goods sold | 528,566 | 510,539 | 1,392,661 | 1,388,323 |
| Gross profit | 334,118 | 273,974 | 988,739 | 816,118 |
| Selling, general and administrative | 139,645 | 137,815 | 427,227 | 380,369 |
| Research and development | 68,374 | 63,352 | 145,774 | 151,356 |
| Intellectual property legal development expenses | 2,193 | 2,437 | 5,822 | 6,221 |
| Acquisition and integration costs | 22,320 | — | 35,073 | — |
| Restructuring and other charges | 936 | 143 | 2,140 | 1,738 |
| Change in fair value of contingent consideration | (6,000) | — | (6,000) | — |
| Charges for property losses and associated expenses | 5,369 | — | 5,369 | — |
| Charges (credit) related to legal matters, net | 6,497 | — | 15,248 | (390) |
| Other operating income | (631) | (117) | (8,870) | (5,239) |
| Operating income | 95,415 | 70,344 | 366,956 | 282,063 |
| Other (expense) income: | ||||
| Interest expense, net | (58,913) | (62,814) | (167,317) | (184,854) |
| Foreign exchange (loss) gain, net | (3,174) | (3,431) | (12,924) | 9,072 |
| Loss on refinancing | (5,760) | (31,365) | (9,270) | (31,365) |
| (Increase) decrease in tax receivable agreement liability | (12,992) | 20,808 | (13,098) | 5,701 |
| Other income, net | 481 | 1,235 | 1,876 | 3,357 |
| Total other expense, net | (80,358) | (75,567) | (200,733) | (198,089) |
| Income (loss) before income taxes | 15,057 | (5,223) | 166,223 | 83,974 |
| Provision for (benefit from) income taxes | 2,751 | (23,355) | 6,303 | 5,614 |
| Net income | 12,306 | 18,132 | 159,920 | 78,360 |
| Less: Net income attributable to non-controlling interests | (19,762) | (15,763) | (47,458) | (41,379) |
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests | (7,456) | 2,369 | 112,462 | 36,981 |
| Accretion of redeemable non-controlling interests | (14,239) | — | (14,239) | — |
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. | $(21,695) | $2,369 | $98,223 | $36,981 |
| Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: | ||||
| Basic | $(0.06) | $0.01 | $0.30 | $0.12 |
| Diluted | $(0.06) | $0.01 | $0.29 | $0.11 |
| Weighted-average common shares outstanding: | ||||
| Basic | 335,733 | 314,168 | 323,724 | 312,998 |
| Diluted | 335,733 | 324,754 | 335,233 | 323,704 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.